A Study About Anticancer Effect Of BZG-4000on A Hepatocellular Carcinoma Xenograft Model

Background/AimsPrimary liver cancer(PLC) is a digestive system malignant tumo-r commom in clinical practice,80%-90%of which are hepatocellular car-cinoma(HCC) showed a trend of rising morbidity worldwide. molecular targeting treatment has been a hot area of research for the therap-y of PLC. BZG-4000is a novel compound which similar in chemical structure with Sorafenib. This study was to efficacy and safety of BZG-4000in the treatment of HepG2human hepatocellular carcinoma xenograft model in nude mice.MethodsThe mice were randomly divided into the following five groups with the use of a randomization chart (n58in each group):high-dose BZG-4000group, medium-dose BZG-4000group, low-dose BZG-4000group, sorafenib group, and model group. The exponentially growing Huh7cells (107cells/mL) with.95%viability were subcutaneously injected into the loose skin between the shoulder blades and left front leg of the recipient mice. Drug trials were started when the tumors reached a volume aro-und500mm3.After21days of treatment, body weights were measured, mice were sacrificed, and the tumors were removed to measuree size,volume and the expression of CD31and VEGF. Tumor size measurements included the length (L) and width (W) measured with calipers, and tumor volume was calculated as (LW’2)/2. Tumor tissues slides were hematoxylin and eosin (HE) stained for histopathological examination-Immunohistochemistry detected CD31expression, and Western blotting measured VEGF protein expression.ResultsThe tumor volume inthe high-dose BZG-4000group (group A) was significantly lower than the control group (P<0.05).Significant loss of tumor weight was observed in mice receiving BZG-4000at a dose of40,20, or10mg/kg/day after21days, compared to the control group. The VEGF protein expression in tumor tissues from BZG-4000treatment groups was significantly lower than the control group (P<0.05). tumor expression of CD31was decreased by BZG-4000treatment compared with the control group (P<0.05).ConclusionsBZG-4000has the potential to inhibit the tumorigenesis of hepatocellular carcinoma in vivo by decreasing the expression of CD31and VEGF.